Status:
COMPLETED
Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Anti Obesity Agent
Eligibility:
MALE
18-45 years
Phase:
PHASE1
PHASE2
Brief Summary
Interaction of GLP-1 and PYY3-36 in the inhibition of food intake in healthy subjects
Detailed Description
PYY3-36 and GLP-1 are two classical gastrointestinal peptides, which are released into the circulation during meals from L-cells of the distal gut; there is compelling evidence that each participates ...
Eligibility Criteria
Inclusion
- healthy male subjects
- no evidence of disease
- no history of gastrointestinal or endocrine disorders
Exclusion
- alcohol and drug abuse
- history of gastrointestinal or endocrine disorders
- female subjects
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00822705
Start Date
August 1 2008
End Date
January 1 2009
Last Update
January 14 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Center, University Hospital Basel
Basel, Canton of Basel-City, Switzerland, 4031